A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations-Reference-Cited by-同舟云学术

A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations

Published:2021-03 Issue: Volume:21 Page:100733
ISSN:2451-8654
Container-title:Contemporary Clinical Trials Communications
language:en
Short-container-title:Contemporary Clinical Trials Communications

Author:

Hardan Antonio Y.,Jo Booil,Frazier Thomas W.^ORCID,Klaas Patricia,Busch Robyn M.,Dies Kira A.,Filip-Dhima Rajna,Snow Anne V.,Eng Charis,Hanna Rabi^ORCID,Zhang Bo,Sahin Mustafa

Funder

PTEN Research

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference30 articles.

1. PTEN-opathies: from biological insights to evidence-based precision medicine;Yehia;J. Clin. Invest.,2019

2. Molecular and phenotypic abnormalities in individuals with germline heterozygous PTEN mutations and autism;Frazier;Mol. Psychiatr.,2015

3. The clinical spectrum of PTEN mutations;Yehia;Annu. Rev. Med.,2020

4. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations;Butler;J. Med. Genet.,2005

5. Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly;Herman;Am. J. Med. Genet.,2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperactivity of mTORC1- and mTORC2-dependent signaling mediates epilepsy downstream of somatic PTEN loss;eLife;2024-03-06

2. Hyperactivity of mTORC1 and mTORC2-dependent signaling mediate epilepsy downstream of somatic PTEN loss;2024-02-13

3. Cancer drug repurposing in autism spectrum disorder;Trends in Pharmacological Sciences;2023-12

4. Hyperactivity of mTORC1 or mTORC2-dependent signaling causes epilepsy downstream of somatic PTEN loss;ELIFE;2023-10-24

5. In Silico Identification of Therapeutic Targets and Novel Drug Candidates for Malignant Peripheral Nerve Sheath Tumors;Frontiers in Bioscience-Landmark;2023-09-24